NASDAQ
1.18USD
-0.02 (-1.67%)
We have scored 12 news catalysts on BioVie Inc. (BIVI) over the past 12 months. The biggest single-day move next to one of them came Apr 11, 2026, when BIVI closed −6.2%: “BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI”. Coverage across the window leans positive (average ticker sentiment +0.55). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9M
P/E
—
EPS
—
Beta
0.73
52W range
0.82-3.79
Day range
1.16–1.25
Open
1.23
Prev close
1.20
Volume
81.2K
Avg volume
3.3M
Dividend
0.00
IPO
2020-09-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BioVie Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BIVI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
